Financial PerformanceKIMMTRAK sales of $94MM beat consensus by 9%, driven by strong ex-US growth due to demand, country expansion, and price negotiations.
Market ExpansionKimmtrak has been approved in 39 countries and launched in 26 to date, with one approval and two launches reported in Q1.
Product DevelopmentThe PRISM-MEL-301 trial represents a key catalyst for the brenetafusp program with dose selection expected to drive further development.